Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

New research finds that GLP-1 receptor agonist medications like Ozempic may help lower your Alzheimer's risk. What doctors ...

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

Dementia, including Alzheimer’s disease and related disorders, is one of the fastest-growing public health concerns globally. It currently affects over 55 million people and is expected to impact 139 ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...